RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
-3.24%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$5.73B
AUM Growth
+$5.73B
(-15%)
Cap. Flow
-$198M
Cap. Flow
% of AUM
-3.45%
Top 10 Holdings %
Top 10 Hldgs %
44.42%
Holding
91
New
5
Increased
15
Reduced
36
Closed
16
Top Buys
| 1 |
Invivyd
IVVD
|
$137M |
| 2 |
Absci
ABSI
|
$93.4M |
| 3 |
LivaNova
LIVN
|
$85.5M |
| 4 |
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
|
$49.2M |
| 5 |
Stevanato
STVN
|
$30M |
Top Sells
| 1 |
DexCom
DXCM
|
$98.4M |
| 2 |
ZY
Zymergen Inc. Common Stock
ZY
|
$60.9M |
| 3 |
SelectQuote
SLQT
|
$46.5M |
| 4 |
Charles River Laboratories
CRL
|
$40.1M |
| 5 |
Cigna
CI
|
$37.9M |
Sector Composition
| 1 | Healthcare | 93.97% |
| 2 | Consumer Staples | 3.39% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
OSH
26
DELISTED
Oak Street Health, Inc.
OSH
| $79.9M | 1.39% |
1,878,520
-424,133
| -18% | -$18M |
|
27
Repare Therapeutics
RPTX
$73.9M
| $67.4M | 1.18% |
2,567,696
-56,700
| -2% | -$1.49M |
|
28
Prothena Corp
PRTA
$452M
| $64.2M | 1.12% |
901,491
-314,166
| -26% | -$22.4M |
|
29
ALX Oncology
ALXO
$54.6M
| $63.8M | 1.11% |
864,435
-49,600
| -5% | -$3.66M |
|
|
NVRO
30
DELISTED
NEVRO CORP.
NVRO
| $63.2M | 1.1% |
542,932
-51,800
| -9% | -$6.03M |
|
31
Annexon
ANNX
$225M
| $62.3M | 1.09% |
3,349,185
-75,853
| -2% | -$1.41M |
|
32
Stoke Therapeutics
STOK
$1.08B
| $60.6M | 1.06% |
2,381,958
-76,600
| -3% | -$1.95M |
|
33
Akero Therapeutics
AKRO
$3.65B
| $60.1M | 1.05% |
2,687,444
-117,500
| -4% | -$2.63M |
|
|
NGM
34
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $52.7M | 0.92% |
2,505,118
-287,330
| -10% | -$6.04M |
|
35
Pliant Therapeutics
PLRX
$105M
| $52M | 0.91% |
3,083,501
-72,900
| -2% | -$1.23M |
|
36
ICU Medical
ICUI
$3.06B
| $51.9M | 0.91% |
222,526
-403
| -0.2% | -$94.1K |
|
|
SLGC
37
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $49.2M | 0.86% |
+3,972,270
| New | +$49.2M |
|
38
Genmab
GMAB
$16.7B
| $49M | 0.85% |
1,120,388
-107,200
| -9% | -$4.68M |
|
39
Elevance Health
ELV
$72.4B
| $47.5M | 0.83% |
127,502
+18,701
| +17% | +$6.97M |
|
40
UnitedHealth
UNH
$279B
| $47.2M | 0.82% |
120,710
+26,245
| +28% | +$10.3M |
|
|
IMGN
41
DELISTED
Immunogen Inc
IMGN
| $46.8M | 0.82% |
8,258,345
-622,600
| -7% | -$3.53M |
|
42
Nuvation Bio
NUVB
$1.08B
| $45.1M | 0.79% |
4,541,009
| – | – |
|
|
EPZM
43
DELISTED
Epizyme, Inc
EPZM
| $38.2M | 0.67% |
7,458,660
-1,056,400
| -12% | -$5.41M |
|
|
MDVL
44
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
| $34.2M | 0.6% |
11,724,726
| – | – |
|
|
TCRR
45
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $32.5M | 0.57% |
3,816,709
+580,900
| +18% | +$4.94M |
|
|
GRTS
46
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $30.5M | 0.53% |
2,821,085
+594,879
| +27% | +$6.42M |
|
|
47
Stevanato
STVN
$6.36B
| $30M | 0.52% |
+1,187,025
| New | +$30M |
|
48
Zymeworks
ZYME
$1.07B
| $25.6M | 0.45% |
882,097
-57,600
| -6% | -$1.67M |
|
49
Neurogene
NGNE
$284M
| $25.4M | 0.44% |
3,507,235
-412,000
| -11% | -$2.98M |
|
50
Immatics
IMTX
$662M
| $25.2M | 0.44% |
1,941,892
| – | – |
|